Introduction
============

Uterine adenomyosis is a benign gynecological disease that occurs in 19.5% of women of childbearing age.[@b1-dddt-11-695] The pathological features of adenomyosis are invasion of the endometrium into the myometrium and ectopic endometrial glands surrounded by hypertrophic and hyperplastic myometrium.[@b2-dddt-11-695] Menorrhagia, pelvic pain, dysmenorrhea, and infertility are the main clinical manifestations.[@b3-dddt-11-695],[@b4-dddt-11-695] Patients with adenomyosis have lower implantation, clinical pregnancy, and ongoing pregnancy rates, and an increased miscarriage rate compared with patients without adenomyosis.[@b5-dddt-11-695] Thus, adenomyosis has a negative effect on female fertility. Several measures have been used to improve pregnancy outcomes, including a levonorgestrel-releasing intrauterine system, surgery, and gonadotropin-releasing hormone (GnRH) agonists.[@b6-dddt-11-695]--[@b10-dddt-11-695]

GnRH agonists are modeled after natural GnRH with chemical modifications of the sixth and tenth amino acids to improve efficacy.[@b11-dddt-11-695] The actions of GnRH agonists are mediated through binding to and activation of the GnRH receptor in different tissues or organs.[@b12-dddt-11-695] The GnRH receptor is predominantly distributed in the pituitary. When GnRH agonists bind to the pituitary GnRH receptor, the receptor initially induces increased secretion of gonadotropin, which is often referred to as the "flare-up effect" and lasts about 10 days. Then another effect, termed "pituitary down-regulation", leads to inhibition of follicle-stimulating hormone and luteinizing hormone secretion and a further decrease in the secretion of ovarian hormones.[@b13-dddt-11-695]

The use of GnRH agonist as a noninvasive and effective therapy for adenomyosis is widespread in assisted reproductive technology.[@b14-dddt-11-695],[@b15-dddt-11-695] However, their mechanism of action is unclear. In the clinic, patients with adenomyosis who undergo GnRH agonist treatment are almost immediately ready for embryo transfer, so it is difficult to obtain endometrial samples for analysis during the window of implantation time. Therefore, mouse models of adenomyosis are a good alternative, but it has not yet been determined whether GnRH agonists improve pregnancy outcomes in mice with adenomyosis. To answer this, we evaluated pregnancy outcomes after GnRH agonist treatment in a mouse model of adenomyosis and used high-throughput RNA sequencing (RNA-Seq) data to compare the transcriptomes of endometrial tissues before and after treatment to investigate the effect of GnRH agonist therapy on endometrial gene expression with the aim of determining its mode of action.

Material and methods
====================

Study design
------------

Our experiments were divided into two parts. In the first part, the pregnancy outcomes were compared between the control group, the adenomyosis group, and the GnRH agonist treatment group. In the second part, RNA-seq-based transcriptome analysis was used to identify differentially expressed genes and affected pathways after GnRH agonist treatment.

Animals and treatment
---------------------

In this study, a mouse adenomyosis model was generated using previously published methods.[@b16-dddt-11-695]--[@b19-dddt-11-695] Five pregnant Institute of Cancer Research strain mice were purchased from Shanghai Laboratory Animal Corporation (Shanghai, People's Republic of China), and each was housed in a single cage during the perinatal period. Female offspring were selected for use in this study. All mice were housed in the same temperature-controlled room, with alternating 12-h light/dark periods, and allowed free access to food and water.

For the first experiment, groups of 16 female neonatal mice were dosed orally with 2.7 μmol/kg tamoxifen (Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., Shanghai, People's Republic of China) suspended in a peanut oil/lecithin/condensed milk mixture (2:0.2:3 ratio, by volume) on days 2--5 after birth (day of birth = day 1). A control group of eight mice were fed the same amount of solvent without tamoxifen. After 75 days,[@b16-dddt-11-695],[@b20-dddt-11-695] the 16 tamoxifen-treated mice were split into two groups. The first group (n=8) received a single 8mg GnRH agonist trip (Ferring GmbH, Kiel, Germany) injected intraperitone.[@b21-dddt-11-695] The second group (n=8) of control mice received the same amount of solvent with no GnRH agonist. Four weeks after the GnRH agonist injection, female mice were mated with male mice from 19:00--07:00 overnight. Females were mated only once, and male mice all had a history of fertility. The following morning, females were checked for the presence of a vaginal plug. The day of vaginal plug formation was considered to be day 1 of pregnancy. Pregnant mice were bred in a single cage and allowed free access to food and water. The average litter size at birth was determined 30 days after mating. The farrowing rate was defined as the total number of litters divided by the total number of matings.[@b22-dddt-11-695]

For the second experiment, 16 newborn female offspring were randomly divided into two equal groups: an untreated adenomyosis model group and an adenomyosis group treated with a GnRH agonist. The mice were then treated as described for the first experiment.

Tissue collection and application
---------------------------------

Mice were euthanized at 19:00--20:00 on day 4 of pregnancy.[@b23-dddt-11-695],[@b24-dddt-11-695] For histology, uteri were removed and fixed in 10% formalin overnight, followed by dehydration in 70% ethanol. The tissues were paraffin embedded, then sectioned and stained with hematoxylin and eosin (H&E) and smooth muscle actin. Three randomly selected sections were chosen for histopathology. These two testing methods were used to determine whether the mouse model of adenomyosis was successfully established. If the two tests were both positive, a diagnosis of adenomyosis was made and the endometrium was used for RNA-seq. The endometrial tissues were scraped off using a curved needle, then snap-frozen in liquid nitrogen and stored at −80°C for RNA-seq.

All experiments were performed under the guidelines of the National Research Council's Guide for the Care and Use of Laboratory Animals and approved by the Institutional Experimental Animals Review Board of Ruijin Hospital affiliated with Shanghai Jiaotong University School of Medicine.

Immunohistochemistry
--------------------

After deparaffinization, sections were incubated in 3% H~2~O~2~ for 30 min to block endogenous peroxidase activity. Sections were rinsed and blocked with 10% normal goat serum (Fuzhou Maixin Biotechnology Development Co., Ltd., Fuzhou, Fujian Province, People's Republic of China) for 30 min, then incubated overnight at 4°C with mouse anti-a-SMA primary antibody (1:2000 dilution; GB13036, Wuhan Goodbio Technology Co., Ltd., Wuhan, Hubei Province, People's Republic of China). After three washes in phosphate-buffered saline, the sections were incubated with the appropriate secondary antibodies (Proteintech Group, Inc., Chicago, IL, USA) for 1 h at room temperature. Mice uteri were then analyzed, focusing on the myometrium. If glandular tissue invading the myometrium was present, the adenomyosis model was considered to be successfully established.

RNA extraction and quality control
----------------------------------

Total RNA was extracted from endometrial tissue from the two groups (each group contained three randomly chosen samples) using TRIzol reagent (Life Technologies, Carlsbad, CA, USA) according to the manufacturer's instructions. The concentration of each sample was measured using a Nano-drop 2000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA). The raw sequencing data were evaluated using FastQC (Babraham Institute, Cambridge, UK). The data included the distribution of nucleotides, position-specific sequencing quality, GC base pairs content, proportion of any general-PCR duplications, and *w*-mer frequencies. These evaluation metrics were used to understand the nature of the data.

RNA-seq analysis
----------------

Raw reads of 50 base pairs or greater that passed filtering were used for mapping. MapSplice,[@b25-dddt-11-695] an efficient splice junction mapper for RNA-seq reads, was used to align the reads and fix gapped alignments. Then, a mapping step was used to identify spliced alignments. We applied the DEseq algorithm[@b26-dddt-11-695] to filter the genes differentially expressed between the two groups using a false discovery rate (FDR) threshold of 0.05.

Cluster analysis
----------------

Cluster analysis was used to identify the global trends and to model profiles of expression. Fisher's exact test and the multiple comparison test[@b27-dddt-11-695],[@b28-dddt-11-695] were applied to identify the statistically significant model profiles.

Gene ontology (GO) analysis
---------------------------

GO analysis was used to analyze the biological implications of unique genes in the significant profiles.[@b29-dddt-11-695] Fisher's exact and chi squared tests were applied to classify significant GO categories, and the FDR[@b30-dddt-11-695] was used to correct the *P*-value. Generally, when the FDR is set low, the *P*-value is more accurate.

Pathway analysis
----------------

Pathway analysis was applied to determine the significant pathways of differentially expressed genes according to Kyoto Encyclopedia of Genes and Genomes (KEGG), MapSplice, and Reactome databases.[@b25-dddt-11-695],[@b31-dddt-11-695],[@b32-dddt-11-695] Fisher's exact test was used to identify significantly enriched pathways, and the threshold of significance was defined as *P*\<0.05 and FDR \<0.05.[@b33-dddt-11-695] The level of enrichment indicates the significance of the altered pathway.

Quantitative reverse transcription PCR (RT-qPCR)
------------------------------------------------

RT-qPCR was performed to validate the gene expression data obtained from deep sequencing. Total mRNA was extracted using TRIzol reagent (Life Technologies) according to the manufacturer's instructions. The first strand of cDNA was synthesized using primers designed in our lab ([Table 1](#t1-dddt-11-695){ref-type="table"}). The RT product was amplified using SYBR Green on a 7500 Real-Time PCR System (Thermo Fisher Scientific Inc. Waltham, MA, USA). All samples were run in triplicate, and relative gene expression was analyzed according to the 2^−ΔΔCt^ method. The housekeeping gene *Actb* was used for normalization of the expression data.

Statistical analysis
--------------------

Statistical differences were analyzed using Statistical Package for the Social Sciences (SPSS) software (17.0) (SPSS Inc., Chicago, IL, USA). Expression levels among different groups were analyzed using an unpaired Student's *t*-test. The results are represented as the mean ± standard deviation (SD), and any differences between means were considered statistically significant at *P*\<0.05.

Results
=======

Modeling results
----------------

The diagnosis of adenomyosis depends on pathological examination and immunohistochemistry. There was a concordance between H&E ([Figure 1](#f1-dddt-11-695){ref-type="fig"}) and smooth muscle actin staining ([Figure 2](#f2-dddt-11-695){ref-type="fig"}). During this experiment, two mice died in the GnRH agonist treatment group. Model establishment was unsuccessful in only one mouse, suggesting that the treatment of neonatal mice with tamoxifen is an effective method of modeling adenomyosis.

Pregnancy outcome
-----------------

Compared with the control group, a significantly lower average litter size was found in the adenomyosis group (7±0.28 vs 11±0.26; *P*\<0.05). However, after GnRH agonist treatment, the average litter size of mice with adenomyosis increased significantly (10±0.28 vs 7±0.28; *P*\<0.05). No significant difference in the farrowing rate was found among these three groups ([Table 2](#t2-dddt-11-695){ref-type="table"}).

Gene expression changes
-----------------------

Compared with the adenomyosis group, 359 genes were at least twofold differentially expressed (*P*\<0.05) in the endometrium of the GnRH agonist treatment group: 218 were downregulated and 141 were upregulated ([Figure 3](#f3-dddt-11-695){ref-type="fig"}). The sequencing data of the present study are available in the Gene Expression Omnibus (GEO) repository (<http://www.ncbi.nlm.nih.gov/geo/info/linking.html>) under accession numbers GSE89463.

Gene ontology analysis
----------------------

Significantly enriched GO terms from the two groups were related to the cell cycle, including protein glycosylation, protein citrullination, the urea cycle, and transmembrane transport ([Figure 4](#f4-dddt-11-695){ref-type="fig"}). GO terms related to inflammation were also enriched. This category included genes involved in the positive regulation of neutrophil chemotaxis.

Pathway analysis
----------------

Pathway analysis was used to identify significantly altered pathways according to the KEGG database. Twenty-eight pathways were significantly enriched with the identified differentially expressed genes: 20 were downregulated and eight were upregulated (*P*\<0.05; [Figure 4](#f4-dddt-11-695){ref-type="fig"}). These altered pathway terms were mainly metabolic pathways such as mucin type O-glycan biosynthesis, folate biosynthesis, and the metabolism of xenobiotics by cytochrome P450. They also included cell proliferation signal pathways such as the Rap1 signaling pathway and phosphatidylinositol 3-kinase-Akt signaling pathway.

Confirmation of RNA-Seq results by RT-qPCR
------------------------------------------

We analyzed the expression of 10 genes by RT-qPCR based on fold changes in expression shown in RNA-Seq and prospective therapeutic value to verify our data. These were *Sprr2a1*, *Pla2g2e*, *Galnt4*, *Mgat4a*, *Muc13*, *Tff1*, *Aldh3b2*, *B4galnt3*, *Abca8b*, and *Cbr2*. The expression ratios of these genes determined by RT-qPCR were consistent with those from RNA-seq analysis ([Figure 5](#f5-dddt-11-695){ref-type="fig"}).

Discussion
==========

Litter size is one important parameter in the assessment of female productivity.[@b34-dddt-11-695] In our present study, litter size was smaller in the adenomyosis group than in the control group, suggesting that adenomyosis is harmful to pregnancy outcome in mice. These results are consistent with the clinical observations in humans that adenomyosis is associated with subfertility through reduced endometrial receptivity and impaired decidualization,[@b35-dddt-11-695] while a separate study reported that adenomyosis is linked to infertility in humans.[@b36-dddt-11-695] To our knowledge, our study is the first to analyze the effect of adenomyosis on pregnancy outcome in a mouse model. Previous research has focused on the relationship between uterine muscle contraction and adenomyosis in mice.[@b19-dddt-11-695],[@b37-dddt-11-695] The mechanisms behind these effects may be related to the induction of inflammatory factors,[@b38-dddt-11-695] the increased production of oxygen free radicals,[@b39-dddt-11-695] and abnormal uterine contraction.[@b40-dddt-11-695] Importantly, we found that the average litter size was increased after GnRH agonist treatment, suggesting that GnRH agonist treatment may improve pregnancy outcome in mice as it does in humans. However, no significant difference in farrowing rate was found among these three groups, possibly because of the small number of female mice in each group.

GnRH agonists inhibit the secretion of follicle-stimulating hormone and luteinizing hormone, and decrease the secretion of ovarian hormones.[@b13-dddt-11-695] These effects are considered to be the main mechanism underlying the treatment of adenomyosis. Like endometriosis, adenomyosis is an estrogen-dependent disorder. Moreover, a high local concentration of estradiol in endometriotic lesions contributes to the progression of endometriosis.[@b41-dddt-11-695] GnRH agonists reduce the estradiol content in endometriotic lesions through pituitary down-regulation, leading to atrophy of ectopic endometrium. Through transcriptomic analysis in the present study, we found that the expression of estrogen-linked genes such as *Tff1* and *Sprr2a1* was significantly decreased in mice treated with a GnRH agonist. These results were verified with GO and pathway interaction analysis.

Many of the genes showing altered expression levels in our study, such as *Aldh3b2*, are involved in the metabolism of xenobiotics through the cytochrome P450 pathway. Cytochrome P450 aromatase is a key enzyme in estrogen biosynthesis that catalyzes the conversion of androgens to estrogens. Using pathway interaction analysis, we found that the cytochrome P450 pathway was significantly altered following GnRH agonist treatment in the adenomyosis mouse model. Our sequencing results are consistent with a previous analysis of cytochrome P450 aromatase expression in endometriotic and adenomyotic tissues.[@b42-dddt-11-695] To our knowledge, Tff1, Sprr2a1, and Aldh3b2 have not previously been implicated in adenomyosis. *Tff1* is an estrogen response gene that has been reported to be a potential tumor marker in the diagnosis of breast cancer.[@b43-dddt-11-695]--[@b45-dddt-11-695] *Sprr2a* is an estrogen-responsive gene[@b46-dddt-11-695] that encodes small proline-rich protein (SPRR)2a, which is a member of the SPRR family. This binds to and activates SH3 domain-containing proteins, resulting in physiological effects in a broad range of tissues.[@b47-dddt-11-695] Apart from its important role as an estrogen moderator, Sprr2a has wound healing and inflammation regulatory functions[@b48-dddt-11-695] We found that *Tff1* and *Sprr2a1* were downregulated in the adenomyosis mouse model, implying that an increased estrogen level is associated with adenomyosis, and that an impaired wound healing ability of the endometrium may be involved in the development of adenomyosis. These findings are consistent with a recent study that identified a "tissue injury and repair" mechanism in the development of adenomyosis, in which uterine peristalsis led to the invasion of endometrial tissue into the myometrium, resulting in adenomyosis[@b49-dddt-11-695] In the present study, *Tff1* and *Sprr2a1* were upregulated following GnRH agonist treatment, suggesting that GnRH agonists may decrease the production of estrogen and improve the repair capacity of the endometrium. Few studies have been carried out into the role of *Aldh3b2*, and these are limited to neuroblastomas[@b50-dddt-11-695] and keratinocytes,[@b51-dddt-11-695] not adenomyosis. Nevertheless, our results, together with previous observations, increase our understanding of the pathogenesis of adenomyosis and the mechanism of action of GnRH agonists in the promotion of wound healing.

Recent studies have shown that the GnRH receptor is expressed in many extrapituitary organs, such as the ovary, endometrium, and prostate.[@b52-dddt-11-695] Rather than using the classical GnRH receptor-signaling pathway, GnRH agonists might therefore act directly on the endometrium through locally expressed GnRH receptors.[@b53-dddt-11-695] A previous study reported that gonadotropin down-regulation was achieved after injection of an GnRH agonist every 12 h for 5 consecutive days in mice.[@b54-dddt-11-695]

The mice in the current study were able to conceive up to 4 weeks after the GnRH agonist injection, suggesting that the pituitary down-regulation effect might have been attenuated or eliminated. It also indicates that other mechanisms or functions might underlie GnRH agonist action in adenomyosis therapy. Recent molecular studies have indicated a direct effect of GnRH agonists on endometrial function. By binding to specific receptors present on the endometrium, the GnRH agonists regulate several paracrine factors such as transforming growth factor, matrix metalloproteinase, and L-selectin, which play important roles in embryo implantation.[@b55-dddt-11-695]

In adenomyosis, the endometrium has been shown to invade hyperplastic myometrial fibers, causing alterations in the junctional zone.[@b56-dddt-11-695] Khan et al[@b12-dddt-11-695] investigated changes in tissue inflammation, angiogenesis, and apoptosis in tissues collected from women with endometriosis, adenomyosis, and uterine myomas. They showed that GnRH agonist therapy significantly reduced inflammatory reactions and induced a remarkable degree of apoptosis in eutopic endometrium and lesions. On the basis of these findings, we hypothesized that GnRH agonists might inhibit the proliferation and induce the apoptosis of eutopic endometrium cells. Our current observation that the expression of *Galnt4*, *Pla2g2e*, and *Mgat4a* decreased after the intraperitoneal injection of a GnRH agonist is in line with these findings because these genes are responsible for cellular protein biosynthesis and ATP metabolism in human endometrial glandular cells. Moreover, these results agree with the GO and pathway interaction analyses, which indicated that a GnRH agonist might play important roles in proliferation, apoptosis, and the cell cycle in endometrial glandular cells.

Our study has two main limitations. The first is the lack of confirmation of our results using human samples. Even though we have shown that mice are a good animal model for studying adenomyosis, they cannot reflect the natural course of the human disease. Hence, any extrapolation of our findings to humans should be done with caution. Therefore, the differentially expressed genes identified in our mouse model should be validated in patients with adenomyosis. Second, the transcriptomic analysis is only a preliminary step that does not reveal the full mechanism of action of GnRH agonists. Genes that are shortlisted by this analysis should be investigated using in vitro or in vivo models involving overexpression/knockdown studies, protein analyses, and functional assays. We plan to carry out these experiments in our future research.

Conclusion
==========

In conclusion, adenomyosis can be detrimental to pregnancy; however, the pregnancy outcome may be improved by GnRH agonist treatment. In addition to the possible reduction of pituitary down-regulation by GnRH agonist therapy, the reduced proliferation and increased apoptosis of endometrial cells may contribute to the treatment of adenomyosis. Our research casts new light on the roles of GnRH agonists, but it is not possible to conclude that these mechanisms explain the improvement in fertility by GnRH agonists because this study is based on transcriptome analysis alone. Further study is needed to clarify the mechanisms through which GnRH agonists act in treating adenomyosis, which may involve the synergistic action of multiple factors.
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![Light microscopy of uteri from the adenomyosis model group and the GnRH agonist treatment group stained with H&E.\
**Notes: A**, **B**: untreated adenomyosis group; **C**, **D**: adenomyosis group treated with GnRH agonist (**A**, **C**: ×40; **B**, **D**: ×100). The arrows in images mean the ectopic endometrial glands.\
**Abbreviations:** GnRH, gonadotropin-releasing hormone; H&E, hematoxylin and eosin.](dddt-11-695Fig1){#f1-dddt-11-695}

![Detection of smooth muscle actin from the adenomyosis model group and the GnRH agonist treatment group by immunohistochemistry.\
**Notes: A**, **B**: untreated adenomyosis group; **C**, **D**: adenomyosis group treated with GnRH agonist (**A**, **C**: ×40; **B**, **D**: ×100). The arrows in images mean the ectopic endometrial glands.\
**Abbreviation:** GnRH, gonadotropin-releasing hormone.](dddt-11-695Fig2){#f2-dddt-11-695}

![Global expression profiles of the adenomyosis group and GnRH agonist-treated group analyzed by cluster analysis.\
**Abbreviation:** GnRH, gonadotropin-releasing hormone.](dddt-11-695Fig3){#f3-dddt-11-695}

![Genes differentially expressed between the adenomyosis group and the GnRH agonist-treated group analyzed by gene ontology and pathways analyses.\
**Abbreviation:** GnRH, gonadotropin-releasing hormone.](dddt-11-695Fig4){#f4-dddt-11-695}

![Ten genes were examined by RT-qPCR analysis based on their fold-change by RNA-Seq and prospective therapeutic value.\
**Note:** \**P*\<0.05.\
**Abbreviations:** GnRH, gonadotropin-releasing hormone; RT-qPCR, Quantitative reverse transcription polymerase chain reaction.](dddt-11-695Fig5){#f5-dddt-11-695}

###### 

RT--qPCR primers used in the study

  Gene symbol                  Forward primer (5′--3′)   Reverse primer (5′--3′)
  ---------------------------- ------------------------- --------------------------
  *Sprr2a1* (NM_011468.4)      TGCTTTGAGCCTTGTCTTCC      CACAGGAGGGCATGTTGAC
  *Pla2g2e* (NM_012044.2)      TGGACGAGACGGATTGGTG       AGGTTGTGGCGAAAGCAGA
  *Galnt4* (NM_015737.4)       CAGACTCAGGGTCTTGCACA      AGCACCGCTGCTCAATATCT
  *Mgat4a* (NM_001290801.1)    ATGAGGCTCCGAAATGGAACT     CCACTCGAAGACGCTCTTTTAG
  *Muc13* (NM_010739.2)        GCCAGTCCTCCCACCACGGTA     CTGGGACCTGTGCTTCCACCG
  *Tff1* (NM_009362.2)         CCCCGGGAGAGGATAAATTG      TAGAAGGGACATTCTTCTTCTTGA
  *Aldh3b2* (NM_001177438.1)   TGTGTAGCCAGGAGATGCAG      GTTGATGATTCTGCCCAGGT
  *Cbr2* (NM_007621.2)         AGGAAGTTCGCAGAGGTTGA      GGCAACTGAGCAGACTAGGA
  *B4galnt3* (NM_198884.1)     CCAAGAAATTGCCCGAAGTA      GCCACACCAGTCTTCAAACA
  *Abca8b* (NM_007621.2)       ACGTCGAGGGAACTCAGAGA      CATTGATGGCAGCTTGAAGA
  *Actb* (NM_007393.5)         AGGGAAATCGTGCGTGAC        CGCTCATTGCCGATAGTG

**Note:** β-actin was used as an internal control.

Abbreviation: RT-qPCR, quantitative reverse transcription PCR.

###### 

Pregnancy outcomes among the three groups

  Pregnancy outcomes        Controlgroup   Adenomyosis group                                        GnRH agonist treatment group                             *P*-value
  ------------------------- -------------- -------------------------------------------------------- -------------------------------------------------------- -----------
  Average litter size       11±0.26        7±0.28[a](#tfn4-dddt-11-695){ref-type="table-fn"}        10±0.28[b](#tfn5-dddt-11-695){ref-type="table-fn"}       \<0.05
  Farrowing rate, % (n/n)   83.33 (5/6)    66.67 (4/6)[a](#tfn4-dddt-11-695){ref-type="table-fn"}   83.33 (5/6)[b](#tfn5-dddt-11-695){ref-type="table-fn"}   \>0.05

**Notes:** Farrowing rate = total number of farrowings divided by the total number of matings. The results are represented as the mean ± standard deviation (SD). *P*\<0.05 was considered statistically significant.

Adenomyosis group vs control group;

GnRH agonist treatment group vs untreated adenomyosis group.

**Abbreviation:** GnRH, gonadotropin-releasing hormone.

[^1]: These authors contributed equally to this work
